The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to pipeline product obeticholic acid (OCA), developed by Intercept Pharmaceuticals, Inc. for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. ... Read more